Abstracts tagged "Clinical practice"

Abstract Number: 2870 • 2018 ACR/ARHP Annual Meeting
Thresholds for Disease Activity Measures DAS28, CDAI, and RAPID3 Do Not Align with Clinical Practice Patterns of Rheumatoid Arthritis (RA) Disease Management Decisions
Brian C. Sauer¹, Chia-Chen Teng, MS¹, Neil A. Accortt², David H. Collier², Tzu-Chieh Lin² and Grant W. Cannon¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Amgen Inc., Thousand Oaks, CA
Background/Purpose: Treatment guidelines recommend using disease activity measures (DAMs) to guide RA therapy, but DAM use in real-world treatment decisions is not defined. We…
Abstract Number: 524 • 2018 ACR/ARHP Annual Meeting
Clinical Course of Interstitial Lung Disease in Rheumatoid Arthritis Patients in Clinical Practice
Cristina Vadillo Font¹, María A Nieto², Dalifer Freites Núñez³, Zulema Rosales Rosado^1,3, Leticia Leon³, Judit Font Urgelles¹, Juan A Jover Jover¹ and Lydia A Alcazar³, ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Chest diseases, Hospital Clínico San Carlos, Madrid, Spain, ³Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: Interstitial lung disease (ILD) is the extra-articular manifestation that most frequently worsens the course of Rheumatoid arthritis (RA) disease. Purpose: To describe the characteristics…
Abstract Number: 2872 • 2018 ACR/ARHP Annual Meeting
Variation in Predictors of Patient and Physician Defined Flares in Rheumatoid Arthritis
Anna O'Connor¹, Joshua Baker², Bryant R. England³, Brian C. Sauer⁴, Grant W. Cannon⁵ and J. Steuart Richards⁶, ¹Department of Rheumatology, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, ³Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁶Pittsburgh VA Medical Center and University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The identification of risk factors associated with flares in RA is challenging because of the use of different composite disease activity scores and a…
Abstract Number: 621 • 2018 ACR/ARHP Annual Meeting
Practical Optimization of Methotrexate Dose Improves Disease Control of Rheumatoid Arthritis Despite Reduction or Discontinuation of Oral Glucocorticoids
Shintaro Hirata¹, Kei Araki¹, Hiroki Kohno¹, Kazutoshi Yukawa¹, Tadahiro Tokunaga¹, Tatsuomi Kuranobu¹, Katsuhiro Oi¹, Yusuke Yoshida¹, Tomohiro Sugimoto¹, Keisuke Oda^1,2, Takaki Nojima^1,3 and Eiji Sugiyama¹, ¹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ²Hiroshima Clinic, Hiroshima, Japan, ³Nojima Internal Medicine Clinic, Hiroshima, Japan
Background/Purpose: Short-term glucocorticoids (GCs) along with methotrexate (MTX) has been recommended for newly onset patients with rheumatoid arthritis (RA) in EULAR recommendation 2016. However, it…
Abstract Number: 2890 • 2018 ACR/ARHP Annual Meeting
Effect of Tapering of Tumor Necrosis Factor Inhibitor on Achieving Inactive Disease in Axial Spondyloarthritis Based on the ‘Treat-to-Target’ Strategy: A Nationwide Prospective Cohort Study
Jun Won Park¹, Min Jung Kim¹, Hyoun-Ah Kim², Kichul Shin³, Yong-Beom Park⁴, Yeong Wook Song⁵ and Eun Young Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ²Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ³Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ⁴Yonsei University College of Medicine, Seoul, Korea, Republic of (South), ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Although recent treatment guideline of axial spondyloarthritis (axSpA) by the European League Against Rheumatism (EULAR) recommended that tapering of tumor necrosis factor inhibitor (TNFi)…
Abstract Number: 1191 • 2018 ACR/ARHP Annual Meeting
The Importance of Quantitative Assessment of Joint/Organ Damage and Patient Distress in Addition to Inflammatory Activity in Routine Clinical Care
Theodore Pincus, Isabel Castrejón and Joel A. Block, Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Quantitative measures such as laboratory tests and pooled indices have advanced clinical rheumatology care far beyond narrative decisions. These measures generally are directed to…
Abstract Number: 1601 • 2018 ACR/ARHP Annual Meeting
Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis: Results from a Cross-Sectional Observational Study in the United States
Philip J. Mease¹, Clive Liu², Evan Siegel^3,4, Heather Richmond⁵, Meijing Wu⁶, Liang Chen⁶, Kevin Douglas⁶ and Benjamin Lockshin⁷, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Bellevue Dermatology Clinic, Bellevue, WA, ³Georgetown University, Washington, DC, ⁴Arthritis and Rheumatism Associates, Rockville, MD, ⁵Clear Dermatology, Houston, TX, ⁶AbbVie Inc., North Chicago, IL, ⁷US Dermatology Partners, Rockville, MD
Background/Purpose: In patients (pts) with psoriatic arthritis (PsA), early diagnosis and effective treatment has been shown to decrease functional disability and structural progression (Gladman DD,…
Abstract Number: 1602 • 2018 ACR/ARHP Annual Meeting
Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Winnie Hua², Robert R. McLean², Peter Hur⁴ and Alexis Ogdie⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, ⁵Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies showed psoriatic arthritis (PsA) patients with enthesitis had greater disease burden than patients without enthesitis, yet it is unknown whether the impact…
Abstract Number: 2155 • 2018 ACR/ARHP Annual Meeting
Diagnosis of Systemic Sclerosis in the United Kingdom: An Observational Study Using the Clinical Practice Research Datalink
Alicia Gayle¹, Nils Schoof², Margarida Alves², Deborah Clarke³, Chris Poole¹, Christina Raabe², Prithwiraj Das¹ and Toby Maher⁴, ¹Boehringer Ingelheim Ltd., Bracknell, United Kingdom, ²Boehringer Ingelheim International GmbH, Ingelheim, Germany, ³Department of Medical Affairs, Boehringer Ingelheim Ltd., Bracknell, United Kingdom, ⁴University College London and Royal Brompton Hospital, London, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease that is characterised by fibroblast dysfunction and excess extracellular matrix deposition that leads to skin thickening and…
Abstract Number: 2348 • 2018 ACR/ARHP Annual Meeting
Prescriber Attitudes and Beliefs about Triple Therapy for Patients with Rheumatoid Arthritis: Knowledge Exchange in Internet Forums and Social Media
Maria A. Lopez-Olivo¹, Jude K. A. des Bordes¹, Gregory Pratt² and Maria Suarez-Almazor¹, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, ²Research Medical Library, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX
Background/Purpose: Several forums on the internet serve as repositories of personal experiences and exchange of health information. Online discussions among healthcare providers about management of…
Abstract Number: 2516 • 2018 ACR/ARHP Annual Meeting
Long-Term Maintenance of Response in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol
Alain Saraux¹, René-Marc Flipo², Francis Fagnani³, Gabrielle Cukierman⁴, Isabelle Bru⁴, Jean-Michel Joubert⁴, Jan-Christof Schuller⁵, Jacques Massol⁶ and Bernard Combe⁷, ¹CHU La Cavale Blanche, Brest, France, ²Hôpital Roger Salengro, Lille, France, ³Cemka-Eval, Bourg-la-Reine, France, ⁴UCB Pharma, Colombes, France, ⁵UCB Pharma, Brussels, Belgium, ⁶CHU de Besançon, Besançon, France, ⁷CHU Lapeyronie, Montpellier, France
Background/Purpose: The safety and efficacy of certolizumab pegol (CZP) for treating patients (pts) with rheumatoid arthritis (RA) are well-established in a clinical trial setting.1,2 However,…
Abstract Number: 2589 • 2018 ACR/ARHP Annual Meeting
Clinical Characteristics and Treatment Profile of Patients with Psoriatic Arthritis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Alexis Ogdie¹, Mei Liu², Sabrina Rebello³, Meghan Glynn², Peter Hur⁴ and Philip J. Mease⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Few real-world studies have characterized patients with psoriatic arthritis (PsA) who initiate secukinumab. This study described characteristics of patients who initiated secukinumab and other…
Abstract Number: 607 • 2017 ACR/ARHP Annual Meeting
Secukinumab Treatment of Psoriatic Arthritis and Moderate to Severe Psoriasis Relieves Anxiety/Depression up to 52 Weeks: An Overview from Secukinumab Phase 3 Clinical Trials
Philip J Mease¹, Mark Lebwohl², Isabelle Gilloteau³, Todd Fox³, Jaime Oliver³, Steffen Jugl³ and Alice B Gottlieb⁴, ¹University of Washington School of Medicine and Swedish Medical Center, Seattle, WA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Novartis Pharma AG, Basel, Switzerland, ⁴Department of Dermatology, New York Medical College, Vallhalla, NY
Background/Purpose: Secukinumab (SEC), a fully human monoclonal antibody selectively neutralizing interleukin-17A, exhibits significant efficacy, with a favorable safety profile, in the treatment of psoriatic arthritis…
Abstract Number: 1559 • 2017 ACR/ARHP Annual Meeting
Residual Disease Activity in Psoriatic Arthritis Triggers Treatment Adjustment in Only a Quarter of Patients in Daily Clinical Practice
Leonieke van Mens¹, Sadaf Atiqi², Inka Fluri², Marleen van de Sande³, Arno van Kuijk⁴ and Dominique Baeten¹, ¹AMC, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands, ³Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Reade, Amsterdam Immunology and Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: With expanding therapeutic possibilities for the treatment of psoriatic arthritis (PsA) it will be increasingly important to determine residual disease and define when to…
Abstract Number: 743 • 2017 ACR/ARHP Annual Meeting
Impact of Detect on Right Heart Catheterization Referral and Results; Data from a Prospective, Unselected, Systemic Sclerosis Cohort
Anna-Maria Hoffmann-Vold¹, Håvard Fretheim², Anders Heiervang Tennøe², Oyvind Midtvedt², Torhild Garen², Einar Gude², Arne K Andreassen² and Øyvind Molberg², ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway
Background/Purpose: The DETECT calculator has been freely available as a tool for earlier detection and diagnosis of pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].